GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:GOVX
- CUSIP: N/A
- Web: www.geovax.com
- Market Cap: $2.29 million
- Outstanding Shares: 58,718,000
- 50 Day Moving Avg: $0.04
- 200 Day Moving Avg: $0.05
- 52 Week Range: $0.03 - $0.11
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 0.04
- P/E Growth: 0.000
- Annual Revenue: $1.08 million
- Price / Sales: 2.12
- Book Value: ($0.02) per share
- Price / Book: -1.77
- EBIDTA: ($2,500,000.00)
- Net Margins: -234.57%
- Return on Assets: -528.59%
- Current Ratio: 0.44%
- Quick Ratio: 0.44%
- Average Volume: 269,168 shs.
- Beta: -0.08
Frequently Asked Questions for GeoVax Labs (OTCMKTS:GOVX)
What is GeoVax Labs' stock symbol?
GeoVax Labs trades on the OTCMKTS under the ticker symbol "GOVX."
How were GeoVax Labs' earnings last quarter?
GeoVax Labs Inc. (OTCMKTS:GOVX) announced its quarterly earnings data on Wednesday, November, 19th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.01. View GeoVax Labs' Earnings History.
Who are some of GeoVax Labs' key competitors?
Some companies that are related to GeoVax Labs include Tokai Pharmaceuticals (NVUS), NeuroMetrix (NURO), Windtree Therapeutics (WINT), Dextera Surgical (DXTR), Critical Outcome T (COTQF), Affymax (AFFY), Adeptus Health (ADPT), Alphatec Holdings (ATEC), Caladrius Biosciences (CLBS), DelMar Pharmaceuticals (DMPI), DNIB Unwind (BIND), Echo Therapeutics (ECTE), Epirus Biopharmaceuticals (EPRS), Heron Therapeutics (HRTX), Luxottica Group SpA (LUX), Mast Therapeutics (MSTX), Parnell Pharmaceuticals Holdings Ltd (PARN) and Secure Point Technologies (IMSC).
Who are GeoVax Labs' key executives?
GeoVax Labs' management team includes the folowing people:
- David A. Dodd, Independent Chairman of the Board
- Robert T. McNally Ph.D., President, Chief Executive Officer, Director
- Mark W. Reynolds CPA, Chief Financial Officer, Corporate Secretary
- Harriet Latham Robinson Ph.D., Chief Scientific Officer, Director
- Randal D. Chase Ph.D., Director
- Dean G. Kollintzas, Independent Director
- John N. Spencer Jr., CPA, Independent Director
How do I buy GeoVax Labs stock?
Shares of GeoVax Labs can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GeoVax Labs' stock price today?
MarketBeat Community Rating for GeoVax Labs (OTCMKTS GOVX)MarketBeat's community ratings are surveys of what our community members think about GeoVax Labs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of GeoVax Labs stock can currently be purchased for approximately $0.04.
Consensus Ratings for GeoVax Labs (OTCMKTS:GOVX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for GeoVax Labs (OTCMKTS:GOVX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for GeoVax Labs (OTCMKTS:GOVX)Earnings History by Quarter for GeoVax Labs (OTCMKTS GOVX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for GeoVax Labs (OTCMKTS:GOVX)
Current Year EPS Consensus Estimate: $-0.120 EPS
Next Year EPS Consensus Estimate: $1.060 EPS
Dividend History for GeoVax Labs (OTCMKTS:GOVX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GeoVax Labs (OTCMKTS:GOVX)
Insider Ownership Percentage: 4.40%Insider Trades by Quarter for GeoVax Labs (OTCMKTS:GOVX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/5/2015||Randal D Chase||Director||Buy||10,000||$0.19||$1,900.00|| |
|4/23/2015||Mark Reynolds||CFO||Buy||30,000||$0.17||$5,100.00|| |
|4/20/2015||Randal D Chase||Director||Buy||30,000||$0.17||$5,100.00|| |
Headline Trends for GeoVax Labs (OTCMKTS:GOVX)
Latest Headlines for GeoVax Labs (OTCMKTS:GOVX)
GeoVax Labs (GOVX) Chart for Sunday, July, 23, 2017